Please find below a list of trials that are currently accruing:
- A Phase I/II Study of SNDX-5613 in People with Recurrent or Persistent Acute Leukemia
- A Phase I Study of BTX-A51 in People with Recurrent or Persistent Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- A Phase IB/II Study of KRT-232 and Cytarabine or Decitabine in People with Acute Myeloid Leukemia
- A Phase I Study of PRT543 in People with Advanced Melanoma and Blood Cancers
- A Phase I Study of CB-5339 for Recurrent or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndromes
- A Phase I Study of CG-806 in People with Acute Myeloid Leukemia
- A Phase I Study of LY3410738 in Patients with Advanced Blood Cancers with IDH1 or IDH2 Mutations
- A Phase I Study of KRT-232 Alone or in Combination with TL-895 in People with Myelofibrosis
- A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
- A Phase I Study of FHD-286 in People with Recurrent or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndromes
If you would like to contact us or refer a patient, please call 646-608-3749.